ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis

Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Zhong, Zhiqing南方医科大学; 汕头大学
Archives of Medical Science2023-3DOI: 10.5114/aoms.2020.99899
9阅读
引用收藏
分享

摘要

Introduction: Membranous nephropathy (MN) is an organ-specific autoim-mune disease, and its prevalence is increasing. B lymphocytes activated by T cells produce antibodies. CD19+/CD20+ plasma cells may contribute to autoantibody and alloantibody production. Rituximab has been effective in treating MN in many clinical trials. Thus, we conducted a meta-analysis to explore the clinical efficacy and safety of rituximab with MN. Material and methods: We searched Embase, PubMed, Cochrane Library and ClinicalTrials.gov without language or publication date limitations. Studies were classified in high-risk, medium-risk and low-risk groups based on base-line proteinuria. Follow-up periods and different administrations of rituximab were also compared. Complete remission (CR) and partial remission (PR) were assessed to measure the efficacy of rituximab, and adverse effects were also extracted. Dichotomous data were expressed by the odds ratio (OR), and the 95% confidence intervals (95% CI) were used for the recruited studies. Results: Fourteen articles, including 17 studies, were included in this meta -analysis. The pooled OR of overall PR and CR remission rate was 0.58 (95% CI: 0.53-0.63; p = 0.003). No studies belonged to the low-risk group. The over-all PR and CR remission rate in the medium-risk group was 0.56 (95% CI: 0.36-0.73; p = 0.57). The pooled OR of overall PR and CR remission rate in the high-risk group was 0.59 (95% CI: 0.53-0.65; p = 0.03). At the 12-month fol-low-up, the pooled OR of overall PR and CR remission rate was 0.51 (95% CI: 0.43-0.59; p = 0.72). At the 24-month follow-up, the pooled OR of overall PR and CR remission rate was 0.71 (95% CI: 0.48-0.86; p = 0.07). The pooled OR of efficacy of rituximab at 375 mg/m2 x 4 was 0.63 (95% CI: 0.55-0.70; p = 0.001). Rituximab was tolerated in MN, and most adverse effects were mild. The pooled OR of infusion reaction rate of rituximab was 0.25 (95% CI: 0.13-0.44; p = 0.01) in MN. The pooled OR of cardiovascular-related event rate of rituximab in MN was 0.04 (95% CI: 0.02-0.11). The pooled OR of in-fection rate of rituximab in MN was 0.06 (95% CI: 0.03-0.12; p < 0.00001). Conclusions: Rituximab is safe and effective in MN and a promising alter-native treatment. More randomized control trials and studies on the role of MN are expected.

学科与关键词

关键词
membranous nephropathyrituximabcomplete remissionpartial remissionmeta -analysis
相关
加载中…
  • Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis
    You, Lu; Ye, Peiyi; Xiao, Guanqing; Liang, Jiabao; Kong, Yaozhong*Turkish Journal Of Medical Sciences, 2021, 51(6): 2870-2880.被引 2
  • Membranous nephropathy
    Ronco, Pierre*; Beck, Laurence; Debiec, Hanna; Fervenza, Fernando C.; Hou, Fan Fan; Jha, Vivekanand; Sethi, Sanjeev; Tong, Allison; Vivarelli, Marina; Wetzels, JackNature Reviews Disease Primers, 2021, 7(1): 69.被引 135
  • Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis
    Wang, Dan; Wang, Lijuan; Zhang, Mingrui; Li, Ping; Zhang, Qinghua; Bao, Kun*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2023, 102(9).
查看全部 →

发表信息

论文状态
公开发表
期刊
Archives of Medical Science
发表日期
2023-03
卷期
第 19 卷, 第 2 期
页码
411-419
DOI
10.5114/aoms.2020.99899
语言
ENGLISH
成果收录
SCIE
资助标注
Natural Science Foundation of the Guangdong Province [2015A030310386]; Guangdong Medical Science and Technology Research Fund Project [A2018336]; Guangzhou Medical Key Discipline Construction Project

作者

  • Z

    Zhong, Hongzhen (第一作者)

    2 · shantou univ

  • L

    Li, Hong-Yan

    southern med univ

查看全部 4 位作者收起作者
  • Z

    Zhou, Tianbiao (通讯)

    2 · shantou univ

  • Z

    Zhong, Zhiqing

    2 · shantou univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417